Table 5. Most frequently reported drug-ADR combinations (Primary and secondary suspected drugs only).

≤27 days	N = 3,274 (%)	28 days—23 months	N = 21,356 (%)	2–11 years	N = 146,094 (%)	12–17 years	N = 129,699 (%)	Total	N = 548,640 (%)
Buprenorphine–Drug withdrawal syndrome neonatal	32 (1.0%)	Valproate—Drug exposure during pregnancy	84 (0.4%)	Atomoxetine–Prescribed overdose	473 (0.3%)	Isotretinoin—Depression	472 (0.4%)	Isotretinoin—Depression	669 (0.1%)
Heparin—Maternal drugs affecting foetus	29 (0.9%)	Fluoxetine- Drug exposure during pregnancy	49 (0.2%)	Atomoxetine–Drug Ineffective	462 (0.3%)	Isotretinoin-Inflammatory bowel disease	337 (0.3%)	Atomoxetine–Drug Ineffective	664 (0.1%)
Heparin—Premature baby	21 (0.6%)	Valproate–Foetal anticonvulsant syndrome	40 (0.2%)	Atomoxetine–Abnormal behaviour	396 (0.3%)	Isotretinoin-Colitis Ulcerosa	257 (0.2%)	Atomoxetine–Prescribed overdose	654 (0.1%)
Levetiracetam—Maternal drugs affecting foetus	17 (0.5%)	Olanzapine—Drug exposure during pregnancy	39 (0.2%)	Methylphenidate–Product quality issue	393 (0.3%)	Isotretinoin-Crohn's disease	234 (0.2%)	Atomoxetine–Abnormal behaviour	579 (0.1%)
Heparin-Caesarean section	14 (0.4%)	Fentanyl–Accidental drug intake by child	38 (0.2%)	Atomoxetine–Somnolence	356 (0.2%)	Isotretinoin-Suicidal ideation	225 (0.2%)	Methylphenidate–Product quality issue	573 (0.1%)

Presented proportion are based on the total number of “primary suspect” and secondary suspect” reported drugs. The number of unique drug-event combinations was 180,100 and within the age groups: 2,606 (0–27 days); 14,800 (28 days-23 months); 62,788 (2–11 years); 59,101 (12–17 years).